![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Enerplus Corporation | NYSE:ERF | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.09 | 0 | 01:00:00 |
Regulatory News:
Eurofins (Paris:ERF):
Eurofins commenced the year with a solid performance in Q1 2023:
Objectives
€m
FY 2023
FY 2027
Revenues
€6.6bn – €6.7bn
Approaching €10bn
Adjusted1 EBITDA3
€1.35bn – €1.4bn
Margin: 24%
FCFF before investment in owned sites8
€700m - €750m
Approaching €1.5bn
Comments from the CEO, Dr Gilles Martin:
“Thanks to the hard work of the Eurofins team and in spite of the challenges presented by the global economy, we started the year in a strong way and delivered organic growth exceeding our objective. While we continue to be cautious in the current uncertain economic climate, we remain confident in our long-term strategy of further investing in our unique laboratory network, innovating and improving services to our clients. In the near term, our focus is very much on continuing our digitalisation initiatives and implementing measures to combat the impact of inflation, in particular aligning prices with inflation and productivity improvements.”
Conference Call
Eurofins will hold a conference call with analysts and investors today at 15:00 CET to discuss the results and the performance of Eurofins, as well as its outlook, and will be followed by a questions and answers (Q&A) session.
Click here to Join Call >> No need to dial in. From any device, click the link above to join the conference call. Alternatively, you may dial-in to the conference call via telephone using one of the numbers below (full list of dial-in numbers available here):
UK: + 44 330 165 4027 US: + 1 323 701 0225 FR: + 33 176 772 274 BE: + 32 240 406 59 DE: + 49 6966 102 480
Confirmation Code: 8377599
Table 1: Organic Growth Calculation and Revenue Reconciliation
In €m except otherwise stated
Q1 2022 reported revenues
1,760
+ 2022 acquisitions - revenue part not consolidated in Q1 2022 at Q1 2022 FX
53
- Q1 2022 revenues of discontinued activities / disposals7
-22
= Q1 2022 pro-forma revenues (at Q1 2022 FX rates)
1,791
+ Q1 2023 FX impact on Q1 2022 pro-forma revenues
16
= Q1 2022 pro-forma revenues (at Q1 2023 FX rates) (a)
1,807
Q1 2023 organic scope* revenues (at Q1 2023 FX rates) (b)
1,571
Q1 2023 organic growth rate (b/a-1)
-13.1%
Q1 2023 acquisitions - revenue part consolidated in Q1 2023 at Q1 2023 FX
3
Q1 2023 revenues of discontinued activities / disposals7
0
Q1 2023 reported revenues
1,574
* Organic scope consists of all companies that were part of the Group as at 01/01/2023. This corresponds to 2022 pro-forma scope.
Table 2: Breakdown of Revenue by Operating Segment
€m
Q1 2023
As % of total
Q1 2022
As % of total
Y-o-Y variation %
Organic growth6 in the Core Business**
Europe
797
50.6%
1,000
56.8%
-20.3%*
+6.0%
North America
607
38.5%
584
33.2%
+4.0%
+9.1%
Rest of the World
170
10.8%
176
10.0%
-3.3%*
+6.0%
Total
1,574
100%
1,760
100%
-10.5%
+7.1%
* Segments most impacted by the sharp decline in revenues from COVID-19 testing and reagents
** Excluding COVID-19 related clinical testing and reagent revenues
1
Adjusted results – reflect the ongoing performance of the mature14 and recurring activities excluding “separately disclosed items”.
2
Separately disclosed items – include one-off costs from integration and reorganisation, discontinued operations, other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, share-based payment charge5, impairment of goodwill, amortisation of acquired intangible assets and negative goodwill, gains/losses on disposal of businesses and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions, net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income), net finance costs related to hybrid capital and the related tax effects.
3
EBITDA – Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, acquisition-related expenses, net and gain and loss on disposal of subsidiaries, net.
4
Net capex – Purchase of intangible assets, property, plant and equipment, less proceeds from the disposal of such assets and less capex trade payables change of the period.
5
Free Cash Flow to the Firm (FCFF) – Net cash provided by operating activities, less Net capex.
6
Organic growth for a given period (Q1, Q2, Q3, Half Year, Nine Months or Full Year) – non-IFRS measure calculating the growth in revenues during that period between 2 successive years for the same scope of businesses using the same exchange rates (of year Y) but excluding discontinued operations.
For the purpose of organic growth calculation for year Y, the relevant scope used is the scope of businesses that have been consolidated in the Group's income statement of the previous financial year (Y-1). Revenue contribution from companies acquired in the course of Y-1 but not consolidated for the full year are adjusted as if they had been consolidated as of 1st January Y-1. All revenues from businesses acquired since 1st January Y are excluded from the calculation.
7
Discontinued activities / disposals: discontinued operations are a component of the Group’s Core Business or product lines that have been disposed of or liquidated; or a specific business unit or a branch of a business unit that has been shut down or terminated, and is reported separately from continued operations. For more information, please refer to Note 2.26 of the Consolidated Financial Statements for the year ended 31 December 2022.
8
FCFF before investment in owned sites: FCFF less Net capex spent on purchase of land, buildings and investments to purchase, build or modernise owned sites/buildings (excludes laboratory equipment and IT).
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins network of companies believes that it is the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With over 61,000 staff across a decentralised and entrepreneurial network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425006095/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620 E-mail: ir@eurofins.com
1 Year Enerplus Chart |
1 Month Enerplus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions